Mechanisms of HERV-K (HML-2) Transcription during Human Mammary Epithelial Cell Transformation – Journal of Virology

Mechanisms of HERV-K (HML-2) Transcription during Human Mammary Epithelial Cell TransformationJournal of VirologyImportantly, LTR-driven transcription was restricted to tumorigenic cells, suggesting that LTR promoter activity is dependent upon the transcriptional environment of a malignant cell. IMPORTANCE Here, we use an in vitro model of human mammary …and more »

Read More

Antisense Oligonucleotide Squelches Huntingtin Protein in Phase 1/2a Trial – Alzforum

Genetic Engineering & Biotechnology NewsAntisense Oligonucleotide Squelches Huntingtin Protein in Phase 1/2a TrialAlzforumAn antisense oligonucleotide knocked down levels of the mutant huntingtin protein in Huntington’s disease patients, who appeared to tolerate treatment well, according to a December 11 announcement by Ionis Pharmaceuticals, Inc., in Carlsbad, California …Incurable Huntington’s disease might finally have a treatmentEconomic TimesRoche Licenses Ionis’ Antisense HD Therapy Following Groundbreaking TrialGenetic Engineering & Biotechnology NewsRoche snaps up Huntington’s drug on positive dataBioPharma DiveMedscapeall 13 news articles »

Read More

Roche Licenses Ionis’ Antisense HD Therapy Following Groundbreaking Trial – Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology NewsRoche Licenses Ionis’ Antisense HD Therapy Following Groundbreaking TrialGenetic Engineering & Biotechnology NewsRoche exercised its option to license Ionis Pharmaceuticals’ Huntington’s disease (HD) antisense drug candidate IONIS-HTTRX on the back of what have been called “groundbreaking” results from a placebo-controlled Phase I/IIa dose-escalation study. Roche …Ionis Pharma licenses IONIS-HTT Rx to Roche following successful phase 1/2a study in patients with Huntington’s …pharmabiz.comRoche Licenses Promising Huntington’s Therapy IONIS-HTTRx, Begins Extension StudyHuntington’s Disease Newsall 3 news articles »

Read More

Recent Study Reveals Growth Prospects of Antisense and RNAi Therapeutics Market During 2015 – 2023 – MilTech

Recent Study Reveals Growth Prospects of Antisense and RNAi Therapeutics Market During 2015 – 2023MilTechThe rising incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases has led to the demand for antisense and RNai therapeutics. The market exhibits a strong pipeline of product and is looking forward to …and more »

Read More

‘Ground-breaking’ new drug gives hope in Huntington’s disease – Cyprus Mail

Cyprus Mail’Ground-breaking’ new drug gives hope in Huntington’s diseaseCyprus MailThere is currently no effective disease-modifying treatment for the condition, with existing medicines focused only on managing disease symptoms. Ionis said Roche would now be responsible for all IONIS-HTT(Rx) development, regulatory and …Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with …Markets InsiderHuntington’s disease: ‘Ground-breaking’ new drug gives hope for patientsABC OnlineBreakthrough drug trial in fight against Huntington´s diseaseDaily MailMetro Newspaper UK -HDBuzz -BBC News -The Guardianall 85 news articles »

Read More

‘Groundbreaking’ New Drug Gives Hope in Huntington’s Disease – Voice of America

Voice of America’Groundbreaking’ New Drug Gives Hope in Huntington’s DiseaseVoice of AmericaThere is currently no effective disease-modifying treatment for the condition, with existing medicines focused only on managing disease symptoms. Ionis said Roche would now be responsible for all IONIS-HTT(Rx) development, regulatory and …Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with …Markets InsiderNew Drug a ‘Ground-breaking’ Advance in Huntington’s DiseaseMedscape’Groundbreaking’ drug offers hope for people with Huntington’sRTE.ieMetro Newspaper UK -HDBuzz -BBC News -The Guardianall 70 news articles »

Read More

UPDATE 1-‘Ground-breaking’ new drug gives hope in Huntington’s disease – Business Insider

FortuneUPDATE 1-‘Ground-breaking’ new drug gives hope in Huntington’s diseaseBusiness InsiderIonis said Roche would now be responsible for all IONIS-HTT(Rx) development, regulatory and commercialisation activities and costs. The drug uses an approach called antisense to stop a gene producing a particular protein. The technique has already led …’Ground-breaking’ new drug gives hope in Huntington’s diseaseReutersIonis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with …PR Newswire (press release)Huntington’s disease: ‘Ground-breaking’ new drug gives hope for patientsABC OnlineBT.com -Metro Newspaper UK -HDBuzz -BBC Newsall 102 news articles »

Read More

‘Ground-breaking’ new drug gives hope in Huntington’s disease – Reuters

Newsweek’Ground-breaking’ new drug gives hope in Huntington’s diseaseReutersThe drug uses an approach called antisense to stop a gene producing a particular protein. The technique has already led to a drug for spinal muscular atrophy that was approved last year. Shares in Ionis rose around 2 percent in early Nasdaq trade as …UPDATE 1-‘Ground-breaking’ new drug gives hope in Huntington’s diseaseBusiness InsiderIonis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with …Markets InsiderNew Drug a ‘Ground-breaking’ Advance in Huntington’s DiseaseMedscapeRTE.ie -Metro Newspaper UK -HDBuzz -BBC Newsall 54 news articles »

Read More

‘Ground-breaking’ new drug gives hope in Huntington’s disease – Reuters

Mirror.co.uk’Ground-breaking’ new drug gives hope in Huntington’s diseaseReutersThe drug uses an approach called antisense to stop a gene producing a particular protein. The technique has already led to a drug for spinal muscular atrophy that was approved last year. Shares in Ionis rose around 2 percent in early Nasdaq trade as …Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with …Markets Insider’Groundbreaking’ drug offers hope for people with Huntington’sRTE.ieSuccess! ASO drug reduces levels of mutant protein in Huntington’s disease patientsHDBuzzall 31 news articles »

Read More

Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on … – GlobeNewswire (press release)

Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on …GlobeNewswire (press release)CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced data from …WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD DisclosureMarket Exclusiveall 19 news articles »

Read More

Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference – Markets Insider

Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceMarkets InsiderIonis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense …Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceGlobeNewswire (press release)all 10 news articles »

Read More